New research launched today by the Centre for Economic and Business Research (Cebr) looking at the costs of cardiovascular disease in six major European markets (France, Germany, Spain, Italy, Sweden and the United Kingdom) which account for 74% of the European Union’s GDP and 64% of its population. Across these six countries, the total financial impact of CVD, including direct and indirect costs, is estimated to be €102.1 billion by the end of 2014. By the end of the decade this is set to rise to €122.6 billion.
- The Cebr research was commissioned by AstraZeneca to gain a better understanding of the direct financial impact of CVD to healthcare systems, alongside the indirect costs from lost productivity due to premature mortality and morbidity.
- The research showed that across the six European economies (France, Germany, Italy, Spain, Sweden and the UK):
Today – 2014
- Direct healthcare costs attributable to CVD total €81.1 billion in 2014; they present the largest cost at 70-80% across all six economies.
- Indirect costs from premature mortality are estimated to be €19.6 billion and indirect costs from morbidity are responsible for the smallest cost, accounting for €1.4 billion.
- Mortality from CVD will come to 1,118,457 today this year. Of the 1,118,457 lives lost to CVD in 2014, 93,584 will be among the working age population.
By the end of the decade – 2020
- Direct healthcare costs attributable to CVD will have cost the healthcare systems of the six countries €98.7 billion by the end of 2020.
- Indirect costs from premature mortality will have cost the economy €22.3 billion in lost productivity through premature mortality by the end of 2020. At the same time, the cost of morbidity related to CVD will have grown to €1.6 billion.
- Mortality from CVD is expected to rise to 1,215,088 in 2020. By 2020 the proportion of deaths among the labour force will increase to 99,743.
Findings by country
- France: total costs from CVD in France in 2014 reach €15.6 billion. This represents 0.8% of the country’s GDP. By 2020 the costs from CVD will have risen to €18.7 billion.
- Germany: Germany faces by far the highest cost from CVD at €37.4 billion in 2014 or 1.4% of GDP. The total cost from CVD is forecast to increase further by 2020, to €41.3 billion.
- Italy: The third highest cost from CVD was found in Italy at €18.3 billion, which equals 1.3% of the country’s GDP. The Total cost from CVD is expected to rise further to €23.0 billion.
- Spain: this year Spain faces a total cost of €7.7 billion, equivalent to 0.7% of GDP. This cost will increase to €10.9 billion by the end of the decade.
- Sweden: in 2014 Sweden is subject to a total cost of €4.3 billion (1% of the country’s GDP). The total cost from CVD is set to rise to €5.3 billion in 2020.
- UK: CVD was responsible for a cost of €18.9billion in 2014, which represents 1.4% of the UK’s GDP. As elsewhere, an increase in the cost from CVD is expected by 2020, to €23.1 billion.
Tom Keith-Roach at AstraZeneca said: “The figures set out in this new study are stark. The financial burden of cardiovascular disease and the human impact on individuals and their families is only set to rise unless we address this epidemic head on. This requires a continued, coordinated focus across industry, academia, healthcare systems and governments. As a pharmaceutical company, we believe it is our responsibility to play an integral role in the prevention and treatment of the disease by pushing the boundaries of science to create life-changing medicines for patients.”
Sandra Bernick, Cebr Economist and lead author of the report, adds: “The costs from cardiovascular disease to the UK economy currently stand at 1.4% of GDP: this is large in comparison with other European nations. Unless actions are taken to address this challenge, the economic burden will become ever more substantial.”
The full research paper and country fact sheets are available to download here